SOLIGENIX INC (SNGX)
US8342235053 - Common Stock
SNGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. SNGX may be in some trouble as it scores bad on both profitability and health. SNGX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SNGX had negative earnings in the past year.
In the past year SNGX has reported a negative cash flow from operations.
SNGX had negative earnings in each of the past 5 years.
In the past 5 years SNGX always reported negative operating cash flow.
1.2 Ratios
SNGX has a worse Return On Assets (-62.67%) than 60.68% of its industry peers.
The Return On Equity of SNGX (-243.41%) is worse than 72.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.67% | ||
| ROE | -243.41% | ||
| ROIC | N/A |
ROA(3y)-68.67%
ROA(5y)-83.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SNGX (11.04%) is better than 74.87% of its industry peers.
SNGX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SNGX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 11.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.28%
GM growth 5Y-1.04%
2. Health
2.1 Basic Checks
SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNGX has more shares outstanding
The number of shares outstanding for SNGX has been increased compared to 5 years ago.
The debt/assets ratio for SNGX has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -33.87, we must say that SNGX is in the distress zone and has some risk of bankruptcy.
SNGX's Altman-Z score of -33.87 is on the low side compared to the rest of the industry. SNGX is outperformed by 91.97% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that SNGX is not too dependend on debt financing.
SNGX's Debt to Equity ratio of 0.40 is on the low side compared to the rest of the industry. SNGX is outperformed by 71.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.87 |
ROIC/WACCN/A
WACC7.8%
2.3 Liquidity
A Current Ratio of 1.55 indicates that SNGX should not have too much problems paying its short term obligations.
SNGX has a worse Current ratio (1.55) than 82.05% of its industry peers.
SNGX has a Quick Ratio of 1.55. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.55, SNGX is doing worse than 80.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.55 |
3. Growth
3.1 Past
SNGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.14%, which is quite impressive.
Looking at the last year, SNGX shows a very negative growth in Revenue. The Revenue has decreased by -12.00% in the last year.
SNGX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.67% yearly.
EPS 1Y (TTM)88.14%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q94.98%
Revenue 1Y (TTM)-12%
Revenue growth 3Y-29.15%
Revenue growth 5Y-30.67%
Revenue growth Q2Q-33.84%
3.2 Future
Based on estimates for the next years, SNGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.60% on average per year.
SNGX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.83% yearly.
EPS Next Y14.82%
EPS Next 2Y13.36%
EPS Next 3Y11.6%
EPS Next 5YN/A
Revenue Next Year0.31%
Revenue Next 2Y11.98%
Revenue Next 3Y7.83%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.
Also next year SNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.36%
EPS Next 3Y11.6%
5. Dividend
5.1 Amount
SNGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOLIGENIX INC
NASDAQ:SNGX (5/6/2024, 12:14:11 PM)
0.4099
+0.01 (+1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.84M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -62.67% | ||
| ROE | -243.41% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 11.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.4 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)88.14%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y14.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-12%
Revenue growth 3Y-29.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y